CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 115 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $285,661 | +36.8% | 19,159 | +0.5% | 0.00% | 0.0% |
Q2 2023 | $208,773 | +174.7% | 19,066 | -22.9% | 0.00% | – |
Q1 2022 | $76,000 | -17.4% | 24,721 | -8.7% | 0.00% | – |
Q4 2021 | $92,000 | +7.0% | 27,065 | +14.6% | 0.00% | – |
Q3 2021 | $86,000 | -34.8% | 23,622 | -22.2% | 0.00% | – |
Q2 2021 | $132,000 | +3.9% | 30,378 | +8.3% | 0.00% | – |
Q1 2021 | $127,000 | -14.8% | 28,039 | +7.9% | 0.00% | -100.0% |
Q4 2020 | $149,000 | +4.9% | 25,981 | +32.6% | 0.00% | 0.0% |
Q3 2020 | $142,000 | +100.0% | 19,592 | -4.1% | 0.00% | – |
Q2 2020 | $71,000 | +255.0% | 20,419 | +51.4% | 0.00% | – |
Q1 2020 | $20,000 | -57.4% | 13,485 | -44.3% | 0.00% | – |
Q4 2019 | $47,000 | -65.2% | 24,195 | -8.5% | 0.00% | -100.0% |
Q3 2019 | $135,000 | -28.6% | 26,444 | +0.3% | 0.00% | 0.0% |
Q2 2019 | $189,000 | -46.6% | 26,360 | -1.2% | 0.00% | -50.0% |
Q1 2019 | $354,000 | +71.0% | 26,682 | +1.2% | 0.00% | +100.0% |
Q4 2018 | $207,000 | – | 26,353 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |